Biotech Companies Making Pharma Interesting Again

Argenx built a focused autoimmune franchise around blocking the neonatal Fc receptor. Vyvgart’s growth gives the company unusually clear economics for biotech.

Intellia is testing gene editing delivered directly inside the body rather than modifying cells in a laboratory. That is the harder and more scalable prize.

Revolution Medicines is testing drugs against RAS-driven cancers once considered unreachable. Strong clinical responses have moved the company beyond an elegant platform story.

CRISPR Therapeutics helped win the first regulatory approvals for a CRISPR-based treatment. The next question is whether editing can become repeatable across diseases.

Beam uses base editing to change single genetic letters without cutting both DNA strands. The promise is greater precision, while delivery and safety remain difficult.

Moderna’s pandemic windfall funded a broad messenger-RNA pipeline in cancer, respiratory disease and rare conditions. The post-Covid reset is testing which programs deserve it.

BioNTech is using messenger RNA, antibodies and cell therapies against cancer. Oncology is a more meaningful long-term test than repeating emergency vaccine revenue.

Recursion combines automated experiments, large biological datasets and machine learning to find drug candidates. The platform only matters if the clinical pipeline produces useful medicines.

Insilico has moved AI-designed molecules into human trials, where biology can finally judge the claims. Reaching that point separates it from software demonstrations.

Alnylam turned RNA interference from a Nobel-winning mechanism into several approved medicines. Commercial execution makes its next pipeline bets easier to trust.